Adherence to American Association for the Study of Liver Diseases guidelines for the management of hepatocellular carcinoma: Results of an Italian field practice multicenter study

Future Oncology

Volumn 9, Issue 2, 2013, Pages 283-294

  Borzio, Mauro ^a,b   Fornari, Fabio ^c   De Sio, Ilario ^d   Andriulli, Angelo ^e   Terracciano, Fulvia ^e   Parisi, Giancarlo ^f   Francica, Gianpiero ^g   Salvagnini, Mario ^h   Marignani, Massimo ⁱ   Salmi, Andrea ^j   Farinati, Fabio ^k   Carella, Alessandra ^l   Pedicino, Claudia ^a   Dionigi, Elena ^a   Fanigliulo, Libera ^c   Cazzaniga, Massimo ^m   Ginanni, Barbara ⁿ   Sacco, Rodolfo ⁿ  

^a Azienda Ospedaliera di Melegnano   (Italy)

^b Presidio Ospedaliero Cernusco sul Naviglio   (Italy)

^c GUGLIELMO DA SALICETO HOSPITAL   (Italy)

^d Ospedale Policlinico   (Italy)

^e Ospedale San Giovanni Rotondo (FG)   (Italy)

^f Ospedale Santa Maria Del Prato   (Italy)

^g Dipartimento di Medicina   (Italy)

^h SAN BORTOLO HOSPITAL   (Italy)

ⁱ Azienda Ospedaliera   (Italy)

^j S Orsola Hospital   (Italy)

^k Policlinico Hospital   (Italy)

^l Ospedale Sant'Anna   (Italy)

^m Ospedale Policlinico   (Italy)

ⁿ CISANELLO HOSPITAL   (Italy)

more..

Author keywords

American Association for the Study of Liver Diseases guidelines; field practice; hepatocellular carcinoma; Italy; liver cancer; management

Indexed keywords

AGED; ARTICLE; CANCER STAGING; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; END STAGE LIVER DISEASE; FEMALE; HUMAN; ITALY; LIVER CELL CARCINOMA; LIVER NODULE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INVASIVE PROCEDURE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SUSCEPTIBILITY WEIGHTED IMAGING;

AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; FEMALE; GUIDELINE ADHERENCE; HUMANS; ITALY; LIVER NEOPLASMS; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; PROSPECTIVE STUDIES;

EID: 84874086723     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.12.183     Document Type: Article

References (35)

1. Bosch FX, Ribes J, Diaz M, Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 127, S5-S16 (2004).
2. El-Serag HB, Mason AC, Key C. Trends in survival of patients with hepatocellular carcinoma between 1977 and 1996 in the United States. Hepatology 33, 62-65 (2001).
3. Bruix J, Sherman M, Llovet JM et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J. Hepatol. 35, 421-430 (2001).
4. Bruix J, Sherman M. Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 42, 1208-1236 (2005).
5. Bruix J, Sherman M. Management of hepatocellular carcinoma, an update. Hepatology 53, 1020-1022 (2011).
6. European Association for the Study of the Liver; European Organisation for Research and Treatment of Cancer. EASL-EORTC' clinical practice guidelines: management of hepatocellular carcinoma. J. Hepatol. 56, 908-943 (2012).
7. El-Serag HB, Siegel AB, Davila JA et al. Treatment and outcomes of treating hepatocellular carcinoma among medicare recipients in the United States: A population-based study. J. Hepatol. 44, 158-166 (2006).
8. Borie F, Bouvier AM, Herrero A et al. Treatment and prognosis of hepatocellular carcinoma: A population based study in France. J. Surg. Oncol. 98, 505-509 (2008).
9. Davila JA, Morgan RO, Richardson PA, Du XL, McGlynn KA, El-Serag HB. Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States. Hepatology 52, 132-141 (2010).
10. Borzio M, Colloredo-Mels G, Pioltelli P, Quagliuolo M; Gruppo Epatologico Lombardo. Epidemiology and outcome of hepatocellular carcinoma in Lombardy. Dig. Liver Dis. 39, 1011-1017 (2007).
11. Rosa I, Denis J, Renard P et al. A French multicentric longitudinal descriptive study of hepatocellular carcinoma management (the CHANGE cohort): preliminary results. J. Hepatology 53, S231 (2010).
12. Buccheri G, Ferrigno D, Tamburini M. Karnofsky and ECOG performance status scoring in lung cancer: A prospective, longitudinal study of 536 patients from a single institution. Eur. J. Cancer 32A, 1135-1141 (1996).
13. Sorensen JB, Klee M, Palshof T, Hansen HH. Performance status assessment in cancer patients. An inter-observer variability study. Br. J. Cancer 67, 773-775 (1993).
14. Stroffolini T, Andreone P, Andriulli A et al. Characteristics of hepatocellular carcinoma in Italy. J. Hepatol. 29, 944-952 (1998).
15. Sangiovanni A, Del Ninno E, Fasani P et al. Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology 126, 1005-1014 (2004).
16. Stroffolini T, Trevisani F, Pinzello GB et al. Changing aetiological factors of hepatocellular carcinoma and their potential impact on the effectiveness of surveillance. Dig. Liver Dis. 43, 875-880 (2011).
17. Mazzaferro V, Regalia E, Doci R et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N. Engl. J. Med. 334, 693-699 (1996).
18. Yao FY, Ferrell L, Bass NM, Bacchetti P, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria. Liver Transpl. 8, 765-774 (2002).
19. Mazzaferro V, Llovet JM, Miceli R et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: A retrospective, exploratory analysis. Lancet Oncol. 10, 35-43 (2009).
20. Mirici-Cappa F, Gramenzi A, Santi V et al.; Italian Liver Cancer Group. Treatments for hepatocellular carcinoma in elderly patients are as effective as in younger patients: A 20year multicentre experience. Gut 59, 387-396 (2010).
21. Santi V, Trevisani F, Gramenzi A et al. Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival. J. Hepatol. 53, 291-297 (2010).
22. Forner A, Vilana R, Ayuso C et al. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology 47, 97-104 (2008).
23. Burrel M, Llovet JM, Ayuso C et al.; Barcelona Clinic Liver Cancer Group. MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation. Hepatology 38, 1034-1042 (2003).
24. Massarweh NN, Park JO, Bruix J. Diagnostic imaging and biopsy use among elderly Medicare beneficiaries with hepatocellular carcinoma. J. Oncol. Pract. 3, 155-160 (2011).
25. Sangiovanni A, Manini MA, Iavarone M et al. The diagnostic and economic impact of contrast imaging technique in the diagnosis of small hepatocellular carcinoma in cirrhosis. Gut 59, 570-571 (2010).
26. Leoni S, Piscaglia F, Golfieri R et al. The impact of vascular and nonvascular findings in noninvasive diagnosis of small hepatocellular carcinoma based on EASL and AASLD criteria. Am. J. Gastroenterol. 105, 599-609 (2010).
27. Vilana R, Forner A, Bianchi L et al. Intrahepatic peripheral cholangiocarcinoma in cirrhosis patients may display a vascular pattern similar to hepatocellular carcinoma on contrast-enhanced ultrasound. Hepatology 51, 2020-2029 (2010).
28. Livraghi T, Meloni F, Di Stasi M et al. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice? Hepatology 47, 82-89 (2008).
29. Massarweh NN, Park JO, Farjah F et al. Trends in the utilization and impact of radiofrequency ablation for hepatocellular carcinoma. J. Am. Coll. Surg. 210, 441-448 (2010).
30. Giannini EG, Bodini G, Corbo M et al. Impact of evidence-based medicine on the treatment of patients with unresectable hepatocellular carcinoma. Aliment. Pharmacol. Ther. 31, 493-501 (2010).
31. Llovet JM, Ricci S, Mazzaferro V et al. SHARP investigators study Group. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378-390 (2008).
32. Cheng AL, Kang YK, Chen Z et al. Efficacy and safety of sorafenib in patient in the Asia-Pacific region with advanced hepatocellular carcinoma. A phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 10, 25-34 (2009).
33. Lencioni R. Second interim results of the GIDEON (Global Investigation of Therapeutic Decisions in HCC and of its treatment with sorafenib) study: Barcelona Clinic Liver Cancer (BCLC) Stage Subgroup Analysis (abstract #6500). Presented at: ESMO-ECCO oncology meeting. Stockholm, Sweden, 23-27 September 2011.
34. Sacco R, Bargellini I, Ginanni B et al. Long-term results of sorafenib in advanced-stage hepatocellular carcinoma: what can we learn from routine clinical practice? Expert Rev. Anticancer Ther. 12, 869-875 (2012).
35. Iavarone M, Cabibbo G, Piscaglia F et al. Fieldpractice study of sorafenib therapy for hepatocellular carcinoma: A prospective multicenter study in Italy. Hepatology 54, 2055-2063 (2011).